The incidence of postoperative periprosthetic femoral fracture following total hip replacement: An analysis of UK National Joint Registry and Hospital Episodes statistics data.

Autor: Lamb JN; Centre for Hip Surgery, Wrightington Hospital, Wigan, United Kingdom.; Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Southmead Hospital, Bristol, United Kingdom., Evans JT; Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Southmead Hospital, Bristol, United Kingdom.; Exeter Medical School, University of Exeter, St Lukes Campus, Exeter, United Kingdom.; National Institute for Health and Care Research Exeter Biomedical Research Centre, Royal Devon University Healthcare NHS Foundation Trust and University of Exeter, Exeter, United Kingdom., Relton S; Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds, United Kingdom., Whitehouse MR; Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Southmead Hospital, Bristol, United Kingdom., Wilkinson JM; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom., Pandit H; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, C/O Chapel Allerton Hospital, Leeds, United Kingdom.
Jazyk: angličtina
Zdroj: PLoS medicine [PLoS Med] 2024 Oct 01; Vol. 21 (10), pp. e1004462. Date of Electronic Publication: 2024 Oct 01 (Print Publication: 2024).
DOI: 10.1371/journal.pmed.1004462
Abstrakt: Background: Postoperative periprosthetic femoral fracture (POPFF) after total hip replacement (THR) requires complex surgery and is associated with a high morbidity, mortality, and cost. Although the United Kingdom based National Joint Registry (NJR) captures over 95% of THRs treated with revision, before June 2023 it did not capture POPFF treated with fixation. We aimed to estimate the incidence and epidemiology of POPFF treated with either surgery in England.
Methods and Findings: We performed a retrospective analysis of a mandatory, prospective database (NJR) linked to Hospital Episode Statistics (HES). All linkable primary THRs between 01/01/2004 and 31/12/2020 were included. Revision or fixation of POPFF were identified using a combination of procedural and diagnosis codes. We identified 809,832 THRs representing 5,542,332 prosthesis years at risk. A total of 5,100 POPFF were identified that had been surgically treated by revision, fixation, or both, and 2,831 of these fractures were treated with fixation alone, meaning 56% were not represented with revision data alone. The incidence of POPFF needing surgery was 0.92 (95% CI 0.90, 0.95) per 1,000 prostheses years. This incidence was higher in patients over the age of 70 at the time of primary THR (1.31 [95% CI 1.26, 1.35] per 1,000 prostheses years) and for patients who underwent THR for hip fracture (2.19 [95% CI 1.97, 2.42] per 1,000 prostheses years). This incidence appears to be increasing year on year. The cumulative probability of sustaining a POPFF within 10 years of THR was 1% and over 15% of patients died within 1 year of surgery for a POPFF.
Conclusions: To date, the incidence of POPFF may have been underestimated with over 50% of cases missed if the case identification in this study is correct. After including these cases, we observed that POPFF is the largest reason for major reoperation following THR and patients sustaining these injuries have a high risk of death. The prevention and treatment of POPFF and requires further resource allocation and research.
Competing Interests: HP is a NIHR senior investigator and MHRA advisor. In the latter role, he advised MHRA regarding the incidence and risk factors associated with the post-operative peri-prosthetic femoral fractures. In particular, this was to identify the risks associated with one of the commonly used stems (CPT manufactured by Zimmer Biomet). This was a voluntary role and no funding from MHRA was/is associated with it. HP (as a Chief Investigator) receives institutional funding from Zimmer Biomet, Depuy Synthes, Allay Therapeutics, Paradigm Pharma and Invibio. In particular, Zimmer Biomet has funded University of Leeds in relation to the on-going and previous research in the field of peri-prosthetic fractures. HP is a paid consultant to Zimmer Biomet for the work in the field of peri-prosthetic fractures and arthroplasty related teaching / training. HP has also received personal funding from the following industry organisations (unrelated to the topic of this work): Invibio, Medacta International, Smith and Nephew, MATOrtho, Microport, Teleflex, Allay Therapeutics and Paradigm Pharmaceuticals. HP has a stock option with Allay Therapeutics. HP holds two patents (through University of Leeds - in the field of implantable sensors and recharging apparatus). None of these roles / funding from any of the industry organisations (either to HP or to his institution) influenced the design; collection, analysis, and interpretation of data presented in this manuscript)
(Copyright: © 2024 Lamb et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje